DEF: Surmodics Sets Annual Meeting for February 6, 2025, Amidst Merger Uncertainty

Surmodics, Inc. has scheduled its annual shareholder meeting for February 6, 2025, as a virtual event, while also navigating a pending merger agreement.

Summary

• Surmodics, Inc. will hold its annual shareholder meeting virtually on February 6, 2025, at 4:00 p.m. Central Time.
• The meeting will include voting on the election of one Class II director, setting the number of directors at five, ratifying the appointment of Deloitte & Touche LLP as the company's independent auditor, and an advisory vote on executive compensation.
• Shareholders of record as of December 12, 2024, are eligible to vote.
• The company is currently in the process of being acquired by BCE Parent, LLC for $43.00 per share in cash, a merger approved by shareholders on August 13, 2024.
• The merger is still subject to regulatory approval and other closing conditions, with an expected completion in the second fiscal quarter ending March 31, 2025.
• Due to the uncertainty surrounding the merger, the board decided to proceed with the annual meeting as usual to allow shareholders to vote on governance and compensation matters.
• The company's fiscal 2024 revenue was $126.1 million, a 5% decrease from fiscal 2023, which included $25.0 million of license fee revenue related to the SurVeil drug-coated balloon.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While the company is progressing with a merger and has made strategic advancements, there are also concerns about revenue decline and regulatory hurdles. The overall tone is neutral, reflecting the complexities of the situation.

Positives

• The company is proceeding with its annual meeting to ensure shareholders can vote on key governance and compensation matters despite the pending merger.
• The merger agreement provides a 41.1% premium to the 30-day volume-weighted average closing price through May 28, 2024.
• The company made significant progress on strategic initiatives, including the launch of Preside coating technology and advancements in clinical trials for SurVeil and Sundance DCBs.
• The company launched the Pounce Venous and Pounce LP Thrombectomy Systems and received FDA clearance for the Pounce XL Thrombectomy System.

Negatives

• The company's fiscal 2024 revenue decreased by 5% compared to fiscal 2023.
• The merger is subject to regulatory approval and other closing conditions, creating uncertainty about its completion.
• The company and an affiliate of Parent each received a request for additional information from the U.S. Federal Trade Commission in connection with the Merger.

Risks

• The merger may not be completed within the anticipated timeframe or at all due to regulatory hurdles and other closing conditions.
• The company's stock price could decline significantly if the merger is not completed.
• The company may be required to pay a termination fee of $20.38 million if the merger agreement is terminated under certain circumstances.
• The announcement and pendency of the merger could negatively impact the company's business, operating results, and stock price.
• The merger agreement places limitations on the company's ability to operate its business and engage in alternative transactions.
• The company faces risks related to pending and future litigation, including those related to the merger.

Future Outlook

The company and Parent currently expect to consummate the Merger in the company's second fiscal quarter ending March 31, 2025, subject to customary closing conditions, including required regulatory approval.

Management Comments

• The Board of Directors determined to proceed with the Annual Meeting on the same timeline as in prior years, to provide our shareholders with the opportunity to vote on the typical governance and compensation matters at an annual meeting.
• We believe that a virtual shareholder meeting provides greater access to those who may want to attend and therefore have chosen this method for our annual meeting over an in-person meeting.

Industry Context

The document reflects the ongoing trend of mergers and acquisitions in the medical device industry, as well as the increasing use of virtual shareholder meetings. The company's focus on innovative medical technologies, such as drug-coated balloons and thrombectomy systems, aligns with the industry's emphasis on advanced treatment options.

Comparison to Industry Standards

• The company's peer group for executive compensation includes companies like Anika Therapeutics Inc., Cerus Corporation, and AtriCure, Inc., which are all medical device and equipment manufacturers and suppliers.
• The company's executive compensation practices, such as the use of stock options and restricted shares, are consistent with industry standards.
• The company's pay-for-performance philosophy, with a substantial portion of executive compensation at risk, is also a common practice in the industry.
• The company's revenue of $126.1 million is within the range of its peer group, but the 5% decrease from the previous year indicates a need for improvement in sales performance.
• The company's strategic initiatives, such as the launch of new medical devices and advancements in clinical trials, are comparable to those of its competitors in the medical device industry.

Related Party Transactions

• Kimberly Brastad, sister of Teryl L.W. Sides, is employed as Senior Director, Education and Organizational Development, with aggregate compensation exceeding $120,000, which was approved by the Audit Committee.

Stakeholder Impact

• Shareholders will have the opportunity to vote on key governance and compensation matters at the annual meeting.
• Employees may experience uncertainty due to the pending merger.
• Customers may be affected by any changes in the company's operations or product offerings.
• Suppliers may be impacted by the merger and any changes in the company's supply chain.
• Creditors may be affected by the merger and any changes in the company's financial structure.

Next Steps

• Shareholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will continue to work towards completing the merger with BCE Parent, LLC.
• The company will continue to execute its strategic initiatives and commercialize its new medical devices.

Key Dates

Keywords

merger, annual meeting, proxy statement, shareholders, executive compensation, directors, Deloitte & Touche LLP, regulatory approval, revenue, thrombectomy, medical devices, stock options, restricted shares